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ABSTRACT
Objective: To examine the psychosocial
consequences of being allocated to the control group
as compared with the screen group in a randomised
lung cancer screening trial.
Method: The Danish Lung Cancer Screening Trial,
a randomised controlled trial, ran from 2004 to 2010
with the purpose of investigating the beneﬁts and
harms of lung cancer screening. The participants in
Danish Lung Cancer Screening Trial were randomised
to either the control group or the screen group and
were asked to complete the questionnaires
Consequences Of Screening and Consequences Of
Screening in Lung Cancer (COS-LC). The
Consequences Of Screening and the COS-LC were
used to examine the psychosocial consequences of
participating in the study, by comparing the control
and the screen groups’ responses at the prevalence
and at the incidence round.
Results: There was no statistically signiﬁcant
difference in socio-demographic characteristics or
smoking habits between the two groups. Responses to
the COS-LC collected before the incidence round were
statistically signiﬁcantly different on the scales
‘anxiety’, ‘behaviour’, ‘dejection’, ‘self-blame’, ‘focus
on airway symptoms’ and ‘introvert’, with the control
group reporting higher negative psychosocial
consequences. Furthermore, the participants in both
the control and the screen groups exhibited a mean
increase in negative psychosocial consequences when
their responses from the prevalence round were
compared with their responses from the ﬁrst incidence
round.
Conclusions: Participation in a randomised controlled
trial on lung cancer screening has negative
psychosocial consequences for the apparently healthy
participantsdboth the participants in the screen group
and the control group. This negative impact was
greatest for the control group.
INTRODUCTION
Screening for cancer is a double-edged
sword.
1 2 It has the potential of resulting in
beneﬁcial effects, in some cases of early
detection leading to better prognosis and less
aggressive treatment. However, cancer
screening also has the potentially harmful
effect of detecting inconsequential cancer too
early, which leads to overdiagnosis and over-
treatment.
3 Furthermore, healthy screening
participants may experience distress due to
false-positive ﬁndings.
4e6
Several aspects have been thoroughly
examined within mammographic screening.
Two studies reported that receiving a normal
screen result might inﬂuence psychological
well-being because women with normal ﬁnd-
ings, participating in breast cancer screening
programmes, found this reassuring.
7 8 In
addition, a recent study indicated that at the
population level, women perceived breast
screening as a reassuring and preventive
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ARTICLE SUMMARY
Article focus
- What are the psychosocial consequences of
being allocated to the control group compared
with the screen group in a randomised lung
cancer screening trial?
Key messages
- Participation in a randomised controlled trial on
lung cancer screening has negative psychosocial
consequences for the apparently healthy partic-
ipants eboth the participants in the screen and
the control groups.
- The negative psychosocial consequences was
greatest for the participants in the control group.
Strengths and limitations of this study
- The study design was a randomised controlled
trial.
- The questionnaire used to measure psychosocial
consequences is a condition-speciﬁc instrument
with high content validity and adequate psycho-
metric properties for participants in lung cancer
screening.
- The randomised design was disturbed by
excluding those with true-positive (lung cancer)
and false-positive screening results from the
analysis.
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Open Access Researchinitiative and/or perceived a lack of the option for
screening as insecure.
9 Moreover, women overestimated
the beneﬁcial effects and underestimated the harmful
effects of screening mammography.
71 0Important sources
of information for the population about the beneﬁts and
harms of breast screening appear to be the media,
together with family and friends.
11 A systematic review on
scientiﬁc articles about breast cancer screening
concluded that these articles tend to emphasise the
beneﬁts of screening over the harms.
12
As screening is directed at apparently healthy individuals
rather than patients, there is a particular ethical responsi-
bility to ensure that participation in screening programmes
is beneﬁcial. During the last decades, there has been a rise
in the implementation of cancer screening programmes in
anticipation of beneﬁts from the early diagnosis of cancer.
Particularly in relation to lung cancer, which is now the
leading cause of death among cancers,
13 there is a wide-
spread interest in clarifying the beneﬁts and harms of
screening.
14e16 Previous non-randomised trials involving
lung cancer screening with spiral CT scanning have indi-
cated that lung cancer screening may lead to harm in the
form of overdiagnosis of inconsequential lung cancer.
17 18
The efﬁcacy of CT screening in reducing lung cancer
mortality is being tested in ﬁve randomised controlled
trials: one from the USA
19 and four European trials,
20e23
including the Danish Lung Cancer Screening Trial
(DLCST).
22 The trial from the USA reported a 20%
reduction in lung cancer mortality.
19
Lay people seem to perceive cancer screening as
predominantly beneﬁcial and something that increases
our safety and health. Comments from participants in the
DLCSTrevealed that many of them think of the study as an
ordinary screening programme rather than a scientiﬁc
trial.
24 In general, studies on healthy persons’ experience
of participating in the control group are sparse. Cancer
patients participating in psychological intervention
research reported disappointment at having been rando-
mised to the control group.
25 Other studies registered that
subjects in the control group were more inclined to gain
access elsewhere to the assistance they had hoped to obtain
by joining the trial.
26 27 One study concerning apparently
healthy smokers’ experience of being allocated to the
control group in a smoking cessation trial concluded that
they were disappointed at being assigned to their group
and had a higher dropout rate than subjects in the inter-
vention group.
28 T h i sc o u l dl e a dt ot h eh y p o t h e s i st h a t
healthy individuals who are participating in a lung cancer
screening trial and who are randomised to the control
group will feel more worried and insecure.
Therefore, the objective of this study was to examine
the psychosocial consequences of being allocated to the
control group compared with the screen group in
a randomised lung cancer screening trial.
MATERIALS AND METHODS
Our a priori hypothesis of this study was that
being randomised to the control group in a lung
cancer screening trial carries negative psychosocial
consequences.
The DLCST was carried out from 2004 to 2010 and
included 4104 participants, who were randomised to
either annually low-dose CT scanning (screen group) or
to the control group, whose members were not offered
CT scanning.
22 Socio-demographic characteristics were
collected at the prevalence round. In order to examine
the psychosocial consequences of participating in the
DLCST, all the participants were asked to complete the
questionnaires Consequences Of Screening (COS) and
Consequences Of Screening in Lung Cancer (COS-
LC).
22 Further details about the DLCST can be found in
the article regarding the prevalence round.
22
The questionnaire COS was completed prior to the
randomisation and before the ﬁrst screening round. In
the following incidence screening rounds, the partici-
pants were asked to complete the COS-LC annually.
Thus, when completing the COS, none of the 4104
participants knew whether or not they were to be
screened. In contrast, the participants were all aware of
their randomisation status when they were asked to
complete COS-LC the following years. Only the
responses from the prevalence round and the ﬁrst inci-
dence round were analysed in the present study.
A longitudinal analysis was carried out by comparing
the responses collected with the COS before the preva-
lence round with the responses collected with the COS-
LC before the ﬁrst incidence round (ﬁgure 1). In the
analysis of the screen group, only those having normal
screening results were included and those with true-
positive and false-positive screening results were
excluded. Hence, the development of psychosocial
consequences after 1 year of participation in the trial was
emphasised. Furthermore, cross-sectional analysis was
conducted comparing the COS responses from the
control group with the COS responses from the screen
group, all responses having been collected before
randomisation (ﬁgure 1). In addition, a cross-sectional
analysis was conducted using data collected with the
COS-LC before the ﬁrst incidence round. In this latter
analysis, the responses from the control group were
compared with the responses from those in the screen
group who had a normal CT scan result in the preva-
lence round (ﬁgure 1).
Questionnaires
The COS-LC is a multidimensional questionnaire
measuring psychosocial consequences in lung cancer
screening. The COS-LC has high content validity and
adequate psychometric properties, statistically validated
with the Partial Credit Rasch model for polytomous
items.
24 The content of the COS-LC was developed on
the basis of the questionnaire Consequences Of
Screening in Breast Cancer: a condition-speciﬁc instru-
ment measuring psychosocial consequences of screening
mammography.
24 29 The COS is the common core
questionnaire of the COS-LC and the Consequences Of
Screening in Breast Cancer, and the COS has shown to
2 Aggestrup LM, Hestbech MS, Siersma V, et al. BMJ Open 2012;2:e000663. doi:10.1136/bmjopen-2011-000663
Psychosocial consequences of allocation in an RCT screening trialbe relevant for persons participating in both breast and
lung cancer screening programmes.
24 29
The COS and the COS-LC are multidimensional
instruments consisting of two parts.
24 29 Part I of the
COS-LC is measuring the psychosocial aspects relevant
for potential screening participants and can be used
before the potential participants are invited to lung
screening, at invitation to screening, at screening and
after screening.
24 In contrast, part II of the COS-LC is
only applicable for participants after a ﬁnal diagnosis:
normal, false-positive and true-positive screening
results.
24 This part is related to the long-term psychoso-
cial consequences of cancer screening itself and is
thereby only applicable to the screen group.
24 29
Therefore, only part I of the COS and the COS-LC,
respectively, was used in the present study.
Part I of the COS encompasses four scales and two
single items: ‘anxiety’, ‘sense of dejection’ and ‘negative
impact on behaviour and sleep’ plus the items ‘busy to
take mind of things’ and ‘less interest in sex’. These four
scales and two single items are also included in part I of
COS-LC. In addition, part I of the COS-LC encompasses
ﬁve additional lung cancer screening-speciﬁc scales:
‘focus on airway symptoms’, ‘introvert’, ‘stigmatisation’,
‘harm of smoking’ and ‘self-blame’. The two single items
and all the items in the nine psychosocial scales have
four response categories: ‘not at all’, ‘a bit’, ‘quite a bit’
and ‘a lot’ scored 0, 1, 2 or 3, respectively. The higher
the score of the outcome, the more negative psychoso-
cial consequences the person has experienced.
Furthermore, the participants were asked to complete
a single item about their self-rated health with ﬁve
response categories going from very good health to very
poor health with a score range from 0 to 4.
Statistics
Socio-demographic characteristics, smoking habits and
psychosocial consequences of screening at the preva-
lence round and the ﬁrst incidence round, respectively,
were compared between the screen group and the
control group either with t test (for interval scale vari-
ables) or c
2 test (for categorical variables). Speciﬁcally,
the COS and the COS-LC scales representing the
dimensions of psychosocial consequences were viewed as
interval scale variables and tested with t tests. The
different developments in the responses to the COS
Figure 1 The recruitment, the
prevalence round and the ﬁrst
incidence round in the Danish
Lung Cancer Screening Trial.
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round between the control and the screen groups were
analysed in a linear regression model on the longitu-
dinal COS data, using generalised estimated equations
methods to account for repeated measurement on the
same individual. From this model, t tests were derived to
test whether these developments were different from
zero for each randomisation group and different from
each other between randomisation groups. The level of
signiﬁcance was p<0.05.
Ethical approval
The DLCST was approved by the Ethical Committee of
Copenhagen County on 31 January 2003 and funded in
full by the Danish Ministry of Interior and Health on 23
June 2004. Approval of data management in the trial was
obtained from the Danish Data Protection Agency on 11
February 2005. The trial is registered in Clinical Trials.
gov Protocol Registration System (identiﬁcation no.
NCT00496977).
RESULTS
Of the 4104 participants, 179 had a positive CT scan in
the ﬁrst round of screening (ﬁgure 1). Subsequent
examinations concluded that 17 had lung cancer and
162 had a false-positive screening result.
22 The 179
participants were excluded from this speciﬁc study
because abnormal CT scans have previously been shown
to result in negative psychosocial consequences with the
possibility of distorting the analysis.
24
The screen group and the control group were
compared regarding socio-demographic characteristics
and smoking habits, to ensure that no systematic differ-
ences could be found (table 1).
There was no statistically signiﬁcant difference in rela-
tion to gender, age, social group, education, employment,
region of residence, living alone or smoking habits.
The comparison of the psychosocial aspects between
the participants in the control group and the participants
in the screen group with negative results measured with
the COS before the prevalence round are listed in table 2.
After controlling for multiple testing, none of the COS
scales or single items demonstrate any statistically
signiﬁcant difference between the control group and the
screen group. The control group reported higher
psychosocial aspects on all scales compared with the
screen group. It is worth noting that randomisation had
not yet been done at this stage.
One year later, at the incidence round, the same
individuals completed the COS-LC (table 3).
Table 3 illustrates the cross-sectional analyses between
the two groups at the incidence round. A statistically
signiﬁcant (p<0.0001) greater number of participants in
the screen group showed up at the ﬁrst incidence
screening round (97.0%) compared with participants
from the control group (91.8%)
The number of participants completing COS and
COS-LC had fallen when comparing the prevalence and
the incidence round.
Notable was the statistically signiﬁcant difference
between the two groups’ responses on the scales:
‘anxiety’, ‘behaviour’, ‘dejection’, ‘self-blame’, ‘focus on
airway symptoms’ and ‘introvert’. There was no statisti-
cally signiﬁcant difference in the scales and single items:
‘sleep’, ‘stigmatisation’, ‘harm of smoking’, ‘busy to take
mind off things’, ‘less interest in sex’ and ‘self-rated
health’.
Table 4 shows the results from the statistical analysis of
the longitudinal development in the responses on COS
and COS-LC from the prevalence round to the incidence
round.
As demonstrated in table 4, the participants in both
the control and the screen groups had a mean increase
in negative psychosocial consequences because there was
a statistically signiﬁcant difference between the preva-
lence and incidence rounds in the scales: ‘behaviour’,
‘dejection’, ‘sleep’, ‘busy to take mind off things’ and
‘less interest in sex’. The mean increase in psychosocial
consequences was also compared between participants
in the control and the screen groups and no statistically
signiﬁcant differences were revealed.
DISCUSSION
This study demonstrated that participation in a rando-
mised controlled trial on lung cancer screening had
negative psychosocial consequences for the apparently
healthy participantsdboth the participants in the screen
and the control groups. This negative impact was
greatest for the participants in the control group.
The randomisation in the DLCST was successful since
there was no statistically signiﬁcant difference between
the screen group and the control group in relation to
socio-demographic characteristics and smoking habits.
However, there was a statistically insigniﬁcant tendency
in all scales and items in the COS, indicating that the
participants in the control group experienced more
negative psychosocial consequences than those in the
screen group. This was surprising since no differences
were seen in the socio-demographic characteristics and
the smoking habits and because all the participants in
the DLCST completed the COS before allocation to
either the screen group or the control group. The scales
and single items in the COS have previously been shown
to be positively correlated in a conﬁrmatory factor
analysis.
30 Due to this positive correlation, it would be
expected that a high mean score in one of the COS
scales would also result in high mean scores in the
remaining COS scales. This could explain the non-
signiﬁcant tendency of higher negative psychosocial
mean scores in the control group compared with the
mean scores in the screen group.
Another hypothetical cause of higher negative
psychosocial mean scores in the control group could be
that some of the participants had knowledge about their
allocation before completing the COS. Therefore, we
have scrutinised the COS responses from the prevalence
round chronologically to see if any time periods were
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Psychosocial consequences of allocation in an RCT screening trialTable 1 Comparisons of socio-demographic characteristics and smoking habits between the participants in the control group
and the participants in the screen group with normal results in the prevalence round
Categories n/n
Control group,
n[2052
Screen group,
n[1873
p Value* n (%)/mean (SD) n (%)/mean (SD)
Socio-demographics
Gender
Male 2052/1873 1120 (54.6) 1073 (57.3) 0.088
Female 932 (45.4) 800 (42.7)
Agey (mean)
2052/1873 57.3 (4.8) 57.2 (4.8) 0.6433
Social groupz
I 2040/1866 141 (6.9) 144 (7.7) 0.8508
II 410 (20.1) 370 (19.8)
III 378 (18.5) 341 (18.3)
IV 552 (27.1) 494 (26.5)
V 282 (13.8) 242 (13.0)
Employed, social group uncertain 168 (8.2) 171 (9.2)
Outside the labour market 109 (5.3) 104 (5.6)
School education
7e9 Grade 2047/1870 716 (35.0) 633 (33.9) 0.1961
10 Grade 790 (38.6) 705 (37.7)
Upper secondary school leaving exam 532 (26.0) 515 (27.5)
Other 9 (0.4) 17 (0.9)
Vocational education
None 2048/1868 201 (9.8) 172 (9.2) 0.2943
Semi-skilled worker 27 (1.3) 19 (1.0)
Vocational training 725 (35.4) 643 (34.4)
Short further education 194 (9.5) 183 (9.8)
Middle range training 539 (26.3) 463 (24.8)
Long further education 225 (11.0) 240 (12.9)
Other 137 (6.7) 148 (7.9)
Employment status
Employed 2046/1868 1325 (64.8) 1264 (67.7) 0.1338
Studying 12 (0.6) 8 (0.4)
Job seeking 104 (5.1) 103 (5.5)
Retired 605 (29.6) 493 (26.4)
Region of habitat
Capital region 2045/1862 1654 (80.9) 1493 (80.2) 0.8755
Region Zealand 349 (17.1) 329 (17.7)
Region of Southern Denmark 28 (1.4) 30 (1.6)
Central Denmark Region 11 (0.5) 7 (0.4)
North Denmark Region 3 (0.2) 3 (0.2)
Living alone
No 2035/1865 1453 (71.4) 1331 (71.4) 0.9817
Yes 582 (28.6) 534 (28.6)
Smoking habits
Smoking status
Current smoker 2052/1873 1579 (77.0) 1411 (75.3) 0.2353
Former smoker 473 (23.0) 462 (24.7)
Smoking historyx (mean)
2048/1872 35.9 (13.4) 36.3 (13.4) 0.3229
Motivation for smoking cessation
Very strong 2022/1856 224 (11.1) 174 (9.4) 0.3780
Strong 503 (24.9) 485 (26.1)
Weak 492 (24.3) 437 (23.6)
Very weak 159 (7.9) 133 (7.2)
No wish to quit 171 (8.5) 165 (8.9)
Current non-smoker 473 (23.4) 462 (24.9)
*p Value from a c
2 test (categorical variables) or a t test (continuous variables).
yAge in years per 2 January 2010.
zAccording to current or last job (when retired).
xPack-years (cigarettes per day/203 smoking years).
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a period of time in the prevalence round where partici-
pants’ responses deviated, indicating a personnel bias.
However, the COS responses in the two groups were
found to be randomly distributed throughout the whole
inclusion period.
A third explanation could be the exclusion of the 179
screen-positive participants since this violates the inten-
tion-to-treat principle. These participants may have had
symptoms of lung cancer already and thereby concerns
about their health and higher COS responses, leaving the
included screen-negative participants with artiﬁcially
lower COS scores than the control participants. However,
an additional analysis including the 179 screen-positive
individuals (results not shown) gave results similar to
those in table 2.
One year later, at the incidence round, 222 had
dropped out of the study, 54 from the screen group and
168 from the control group. Hence, the dropout rate was
higher in the control group than in the screen group,
which might be caused by disappointment at being
allocated to the control group. Previous studies have
registered disappointment of being randomised to the
control group because participants joined the trial as
they felt they needed the intervention offered to the
intervention group.
28 31 The explanation could also be
Table 2 Comparisons at the prevalence round of the COS outcomes between the groups of the DLCST study
Range of values n/n
Control group,
n[2052
Screen group,
n[1873
p Valueyz Mean (SD) Mean (SD)
COS scales
Anxiety 0e18 1995/1823 1.61 (2.31) 1.48 (2.20) 0.0748
Behaviour 0e21 2018/1838 0.84 (2.08) 0.72 (1.78) 0.0456
Dejection 0e18 2024/1841 1.37 (2.17) 1.21 (1.99) 0.0254
Sleep 0e12 2019/1849 0.70 (1.72) 0.63 (1.56) 0.1957
Single items
Busy to take mind of things 0e3 2036/1854 0.23 (0.62) 0.21 (0.58) 0.3066
Less interest in sex 0e3 2035/1858 0.48 (1.17) 0.45 (1.13) 0.2873
Self-rated health 0e4 2042/1865 0.97 (0.77) 0.95 (0.74) 0.5977
yp Value from a t test.
zControlling for multiple testing by setting the false discovery rate to maximum 5% with the method of BenjaminieHochberg, the signiﬁcance
level was taken to be p<0.0071.
COS, Consequences Of Screening; DLCST, Danish Lung Cancer Screening Trial.
Table 3 Comparisons at the incidence round of the Consequences Of Screening in Lung Cancer (COS-LC) questionnaire
outcomes between the participants in the control group and the participants with normal screening results in the screen group of
the DLCST study
Range of values n/n
Control group,
n[1884
Screen group,
n[1817
p Valueyz Mean (SD) Mean (SD)
COS scales
Anxiety 0e18 1437/1749 1.71 (2.79) 1.50 (2.52) 0.0263*
Behaviour 0e21 1426/1741 2.02 (3.04) 1.76 (2.85) 0.0129*
Dejection 0e18 1451/1760 1.88 (2.98) 1.61 (2.71) 0.0085*
Sleep 0e12 1454/1765 1.79 (2.57) 1.64 (2.47) 0.1032
COS-LC scales
Self-blame 0e15 1468/1756 2.62 (3.75) 2.32 (3.53) 0.0202*
Focus on (airway)
symptoms
0e24 1446/1749 3.80 (3.93) 3.30 (3.58) 0.0002*
Stigmatisation 0e12 1458/1760 1.25 (2.41) 1.16 (2.26) 0.2821
Introvert 0e18 1453/1763 2.22 (2.96) 1.89 (1.76) 0.0007*
Harm of smoking 0e6 1473/1785 1.63 (1.75) 1.53 (1.66) 0.0880
Anxiety+x 0e21 1431/1743 1.77 (2.93) 1.55 (2.67) 0.0238*
Single items
Busy to take mind off things 0e3 1456/1758 0.30 (0.66) 0.27 (0.63) 0.0799
Less interest in sex 0e3 1465/1774 0.66 (1.29) 0.66 (1.33) 0.9221
Self-rated health 0e4 1476/1780 0.97 (0.80) 0.93 (0.80) 0.1592
yp Value from a t test.
zControlling for multiple testing by setting the false discovery rate to maximum 5% with the method of BenjaminieHochberg, the signiﬁcance
level was taken to be p<0.0269 (indicated by*).
xThe COS anxiety scale with an extra item: shocked.
COS, Consequences Of Screening; DLCST, Danish Lung Cancer Screening Trial.
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obliged to participate in follow-up assessments, whereas
participants in the control group felt less obliged to do
so.
32 In a mammographic study, it was found that those
who dropped out were less able to cope with anxiety and
had higher levels of fatalism.
33 Another cohort study in
urologic disease concluded that men who dropped out
were more likely to have moderate/severe symptoms and
lower socioeconomic status.
34
If the participants who dropped out in the DLCST
were accordingly different when compared with those
who continued to attend the screening trial, this might
have underestimated the differences in the negative
psychosocial consequences between the control group
and the screen group.
A substantial participation bias was identiﬁed in
a study where the 4104 participants in the DLCST were
comparable with current and former smokers in the
general population.
35 Generally, the DLCST participants
had a different socio-demographic make-up, higher
socioeconomic status and reported fewer negative
psychosocial aspects compared with the ordinary heavy
smokers from the general population.
35 This might also
have biased the results in the present study. In addition,
the participants who dropped out in the ﬁrst incidence
round might have been persons with more morbidity
and lower socioeconomic status. Therefore, the negative
psychosocial consequences of the randomisation to the
control group might have been even greater in a repre-
sentative group of former and current smokers.
The present study established a statistically signiﬁcant
difference between the control group and the screen
group regarding experiences of participating in the
screening trial. The results of these analyses seemed to
conﬁrm our a priori hypothesis that healthy individuals
who were participating in a lung cancer screening trial
and who were randomised to the control group would
gain feelings of worry and insecurity.
The level of negative psychosocial consequences was
higher in the control group compared with the screen
group. However, responses collected before the preva-
lence round indicated a non-signiﬁcant tendency that
individuals in the control group experienced more
negative psychosocial consequences, which might have
inﬂuenced the statistically signiﬁcant differences found
in data collected before the incidence round.
The longitudinal analyses revealed that both the
control group and the screen group reported statistically
signiﬁcantly more negative psychosocial consequences
when their responses before the prevalence round were
compared with their responses 1 year later. This
increasing negative psychosocial impact during 1 year
of participation was not statistically signiﬁcantly
different when the two groups were compared. Never-
theless, the control group reported a higher increase in
negative psychosocial scores during this year on all COS
scales. This indicated that the participants in the control
group experienced more negative psychosocial conse-
quences in the ﬁrst year of participation in the DLCST
compared with those in the screen group. Negative
psychosocial consequences were likewise reported from
women not having the option to participate in an
implemented breast cancer screening programme.
9
Conversely, a CT scan with a negative result could have
the beneﬁt of reassuring the participants that they were
healthy. In cervical cancer screening, women partici-
pated to acquire feelings of conﬁdence and security
and they returned to regular screening to conﬁrm that
they were healthy.
36 However, the present study
demonstrated that participants in the screen group who
had a normal CT scan also experienced negative
psychosocial aspects.
Table 4 Mean increase from the prevalence round to the incidence round in the Consequences Of Screening in Lung Cancer
(COS-LC) questionnaire outcomes in the participants in the control group and the participants with negative screening results in
the screening group of the DLCST study
Range of
values
Control group,
n[2052
Screen group,
n[1873
p Value{
Mean
increase (SE) p Valueyz
Mean
increase (SE) p Valuezx
COS scales
Anxiety 0e18 0.1275 (0.0689) 0.0644 0.0299 (0.0657) 0.6493 0.3056
Behaviour 0e21 1.1962 (0.0770) <0.0001* 1.0535 (0.0690) <0.0001* 0.1681
Dejection 0e18 0.5371 (0.0750) <0.0001* 0.4076 (0.0686) <0.0001* 0.2031
Sleep 0e12 1.1025 (0.0651) <0.0001* 1.0271 (0.0585) <0.0001* 0.3887
Single items
Busy to take mind off things 0e3 0.0760 (0.0189) <0.0001* 0.0539 (0.0173) 0.0019* 0.3903
Less interest in sex 0e3 0.1811 (0.0348) <0.0001* 0.2253 (0.0318) <0.0001* 0.3490
Self-rated health 0e4 0.0196 (0.0185) 0.2898  0.0270 (0.0165) 0.1018 0.0605
yp Value from a t test pertaining to the increase in the control group.
zControlling for multiple testing by setting the false discovery rate to maximum 5% with the method of BenjaminieHochberg, the signiﬁcance
level was taken to be p<0.0238 (indicated by*).
xp Value from a t test pertaining to the increase in the screen group.
{p Value from a t test pertaining to the difference in increase between the control and the screen groups.
COS, Consequences Of Screening; DLCST, Danish Lung Cancer Screening Trial.
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Psychosocial consequences of allocation in an RCT screening trialIt is worth noticing that the control group in this trial
completed the COS and the COS-LC annually and
performed spirometry after completing the COS and the
COS-LC. This intervention could be the cause of
the reported negative psychosocial consequences in the
control group. The intervention might have made the
participants anxious because their lung function might
have dropped as a well-known complication of smoking.
In contrast to the screen group, they did not obtain the
knowledge of having a normal CT scan. However, the
analyses of COS cannot distinguish the reasons for
the reported negative psychosocial consequences.
The COS and COS-LC are condition-speciﬁc multidi-
mensional questionnaires where the content of the
scales and the items were found highly relevant in focus
group interviews with participants from the DLCST.
24 It
is well known that condition-speciﬁc questionnaires are
more sensitive than generic questionnaires.
37 Further-
more, generic questionnaires might lack content validity
in a setting of cancer screening.
38 In addition, generic
questionnaires can have inadequate psychometric prop-
erties when they are used in other settings than they
were developed for.
39 This might explain why we have
been able to identify that participation in lung cancer
screening has negative psychosocial consequences in
contrast to the BelgiumeDutch lung cancer screening
trial that mostly have used generic Health Related
Quality of Life questionnaires.
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At the ﬁrst incidence round, statistically signiﬁcant
differences of 0.2e0.7 in the mean scores were identiﬁed
between the participants in the control group and the
participants with normal screening results in the screen
group (see table 3). This corresponds to every ﬁfth to
every second participant in the control group
responding ‘a bit’ to one item in each scale compared
with the response ‘not at all’ among the same number of
participants in the screen group having a normal result.
The statistically signiﬁcant mean increase in scores from
the prevalence round to the ﬁrst incidence round in
both the control group and the screen group were from
0.4 to 1.2 (see table 4). This corresponds to a shift in
responses from ‘not at all’ to ‘a bit’ in one item in each
scale for every second participant to all participants. We
regard these differences as relevant because none of the
persons have experienced a trauma in relation to lung
cancer screening programme, for example, diagnosis of
lung cancer or a false-positive screening result. We also
think that a negative impact illustrated by a change from
‘not at all’ to ‘a bit’ in one item in each psychosocial
scale for 2000 to 4000 healthy screening participants may
well have social signiﬁcance.
CONCLUSIONS
Participation in a randomised controlled trial on lung
cancer screening has negative psychosocial conse-
quences for the apparently healthy participantsdboth
the participants in the screen and the control groups.
This negative impact was greatest for the participants in
the control group.
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